AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00937560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab was supplied as a sterile solution for infusion.
Study NCT00937560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel was supplied locally in commercial batches.
Study NCT00937560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin was supplied locally in commercial batches.
Study NCT01836887 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Very low polyphenol fruit based drink (control)
Study NCT01836887 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Polyphenol-enriched fruit-based drink - low
Study NCT01836887 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Polyphenol-enriched fruit-based drink - high
Study NCT06554002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Participants will be asked to consume glucose on a daily basis (twice per day) for the entire 8 weeks. The supplement will be packed in sachets, and it can be dissolved in water to be consumed as a beverage. Two sachets will be consumed daily.
Study NCT02973321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Orally administered at a stable dose , >=1500 mg daily stable dose or maximal tolerated dose.
Study NCT03856593 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard letter
Description: The standard letter will be signed by the Chief Medical Examiner-Coroner and County Health Officer of Los Angeles County to notify prescribers of the death in their practice. The letter includes the decedent's name, date of birth and date of death, and outlines the annual number and types of prescription drug deaths seen by the medical examiner, discusses the value of and way to access the State's prescription drug monitoring program and includes five Centers for Disease Control and Prevention (CDC) guideline-recommended safe prescribing strategies: 1) Avoid co-prescribing of opioids with benzodiazepines, 2) prescribe minimal dose necessary for acute pain, 3) consider slow tapers with pauses to below 50 morphine milligram equivalents (MME) per day, 4) avoid prescriptions lasting greater than 3-months for pain, and 5) prescribe naloxone in conjunction with opioids for patients taking > 50 MME per day. The letter also states that CURES review is required by law as of October 2, 2018.
Study NCT06554002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Participants will be asked to consume a resistant dextrin on a daily basis (twice per day) for the entire 8 weeks. The test supplement will be packed in sachets, and it can be dissolved in water to be consumed as a beverage. Two sachets will be consumed daily.
Study NCT00406783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-mg Desloratadine
Description: 5-mg Desloratadine tablet, once daily for 15 days
Study NCT00406783 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet, once daily for 15 days
Study NCT00661245 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOGA
Description: Transoral Gastroplasty (TOGA®) System for gastric stapling.
Study NCT00661245 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: The control device (bougie dilator) is a FDA-cleared (Class II) device.
Study NCT00583440 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-step facilitation
Description: 12 weekly individual 12-step facilitation sessions
Study NCT00583440 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Usual clinical treatment in a dual diagnosis treatment program
Study NCT00074724 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Artery Bypass
Description: coronary revascularization using arterial or vein conduits
Study NCT00074724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modern medical management
Description: Therapies with evidence-based recommendations.
Study NCT00074724 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dobutamine echocardiography
Description: Incremental dose administration of dobutamine to elicit a contractile response of the myocardium.
Study NCT00074724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal medical therapy
Description: All medical interventions known to improve outcomes in patients with ischemic left ventricular dysfunction.
Study NCT03856593 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comparator letter
Description: The comparator letter includes all the details in the standard letter plus additional text involving an if/when/then statement along with an injunction to providers to share safety information with patients so that they identify as a safe prescriber. Specifically, the additional text reads as follows: When your next patient presents with pain, keep the above 5 recommendations close at hand to assist with their safe care. Also, be comfortable voicing your concern about prescribing safety with them so that they are also aware of the dangers scheduled drugs may carry. If/when/then is a form of pre-suasion that provides simple rules that tie goals to specific actions and has been used successfully to encourage behavior in many areas including medication adherence and drug abuse rehabilitation.
Study NCT03399240 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitasitiq device
Description: Participant uses Vitastiq device for about 2 months to perform Vitastiq readings every day, preferably in the morning. On day 1, 29 and 57 participants' blood sampling is collected and analysed, and measurements using Vitastiq device are performed.
Study NCT01843686 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magellan®
Description: Autologous Platelet Rich Plasma Prepared Using the Magellan System
Study NCT01843686 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Saline Gel and Usual and Customary Standard of Care
Study NCT03204071 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: Oral prophylaxis followed by Placebo gel to be delivered in intrabody sites of chronic periodontitis subjects.
Study NCT03204071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aloevera
Description: Oral prophylaxis followed by placement of aloevera gel
Study NCT03204071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Oral prophylaxis followed by placement of metformin gel
Study NCT01875471 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: delefilcon A
Description: Daily disposable soft contact lens to be worn at least 8 hours daily
Study NCT01875471 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: narafilcon A
Description: Daily disposable contact lens to be worn at least 8 hours daily
Study NCT02121561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Acceptance Group Therapy
Description: SAGT is an 8-week group therapy for persons with high levels of shame focused on providing psychoeducation regarding shame and self-acceptance and teaching skills for effectively responding to shame. SAGT is based on a cognitive-behavioral framework. Group members are taught how to recognize and challenge shame-eliciting thoughts, effectively discuss shame-eliciting topics with others, and build self-acceptance. Group members also complete weekly homework assignments that allow them to practice their new skills. All sessions include a review of homework and previously discussed concepts, introduction of new material, and in-session discussions/activities. The content of SAGT includes: defining self-acceptance and recognizing shame; increasing balanced thinking about oneself; improving social connections; increasing skillful interpersonal disclosure; challenging unhelpful expectations; handling setbacks; review and commitment to future practice.
Study NCT01334710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib and OSI-906
Description: Sorafenib - 400 mg twice daily OSI-906 - 150 mg twice daily
Study NCT00842530 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYD Dengue Vaccine
Description: 0.5 mL, Subcutaneous
Study NCT00842530 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Inactivated rabies virus vaccine
Description: 0.5 mL, Subcutaneous
Study NCT00842530 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium chloride 0.9%
Study NCT02464826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nailprotex
Description: Nailprotex apply to the abnormal nail twice daily
Study NCT03400280 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best practice algorithm for postoperative care
Description: See arm/group description
Study NCT01014962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albaconozole
Description: Albaconozole 400 mg oral once daily for 5 days
Study NCT01014962 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral once daily for 5 days
Study NCT01014962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albaconozole
Description: Albaconozole 400 mg every 12 hours for 5 days
Study NCT01014962 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral every 12 hours for 5 days
Study NCT01014962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albaconozole
Description: Albaconozole 400 mg oral every 8 hours for 5 days
Study NCT01014962 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral every 8 hours for 5 days
Study NCT04821765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: 200mg, d1, q3W
Study NCT04821765 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Description: 50-60Gy (BED) was given (1.8-2 Gy or 3-4Gy once daily , 5 days a week
Study NCT04821765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel
Description: 150mg/m2, d1, q3W
Study NCT04821765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m2, d1, q3W
Study NCT02255188 — intervention group
Intervention type: PROCEDURE
Intervention: blood sampling procedure
Description: 30 ml of venous blood will be collected from all voluteers using a special vacuum tubes after informed consent. Blood sampling is carried out from an arm vein. All subsequent studies will be executed in the laboratory diagnostic division of Novosibirsk Research Institute of Circulation Pathology and the presence of the donors is unnecessary
Study NCT00572117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topiramate
Description: Medication will be slowly increased over 5 weeks from 25 mg a day to 150 mg twice a day in an effort to minimize side effects that might enable participants and raters to guess whether they are on active drug or placebo. Subjects will continue on 150 mg twice a for Weeks 6-12 of the study.
Study NCT00572117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Medication will be slowly increased over 5 weeks from 25 mg a day to 150 mg twice a day in an effort to minimize side effects that might enable participants and raters to guess whether they are on active drug or placebo. Subjects will continue on 150 mg twice a for Weeks 6-12 of the study.
Study NCT00767520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane + Dasatinib
Description: Tablets, Oral, Exemestane 25 mg + Dasatinib 100 mg, once daily, until disease progression or unacceptable toxicity
Study NCT00767520 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Exemestane + Placebo
Description: Tablets, Oral, Exemestane 25 mg + Placebo 100 mg, once daily, until disease progression or unacceptable toxicity
Study NCT02281331 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Supplement
Description: supplement/placebo plus exercise training
Study NCT02281331 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Supplement
Description: supplement/placebo plus exercise training
Study NCT03914768 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunomodulatory DC vaccine to target DIPG and GBM
Description: This study will inject DC vaccine cells near lymphoid tissue close to the tumor. The patient will receive intravenous cyclophosphamide (200 mg/m2) or oral (cytoxan) before the vaccine, followed by DC vaccine and intravenous bevacizumab (15 mg/kg) the next day. The cells will be repeatedly infused every month for six consecutive months depending on the response and the condition of the patient. The amount of DC vaccine cells per injection is based on prior report at 5-10x106. An initial dose escalation scheme will be imposed.
Study NCT04462484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: videoconference
Description: The intervention is a person-directed, individual, primary occupational intervention. It will be carried out via videoconference in six sessions of 45 minutes (on a weekly basis). Through guided dialogue, individual difficulties and opportunities of each subject will be examined in order to gain self-awareness of personal characteristics (strengths, limitations, maximum workload capacity) in their particular set of job demands and resources. Participants are encouraged to adopt the set of self-care strategies in each dimension, adapting them to their specific context. Activities will be carried out in Spanish by the researcher.
Study NCT02044432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ginger compress
Description: Kidney ginger compress
Study NCT02471937 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacteriological analyses on clinical samples performed with Eswabs
Description: Clinical samples analysed :~mothervagina, breast milk, baby oral cavity, baby stool. Techniques: bacteriological cultures, Real time PCR
Study NCT02502734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate
Description: FF will be provided as a dry powder inhaler containing 50 μg of FF as a dry white powder per blister, to be inhaled orally via ELLIPTA.
Study NCT02502734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be provided as dry powder inhaler containing placebo as a dry white powder per blister, to be inhaled orally via ELLIPTA.
Study NCT02502734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Salbutamol will be provided as a inhaler.
Study NCT00811434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose
Description: 1.5cc/kg/day po for three months
Study NCT00811434 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1.5 ml sugar water/kg day for three months
Study NCT02025231 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy
Description: Study group 1: 3.5 Gray x 10, 5 fractions per week. Study group 2: 3.5 Gray x 10 + 7 Gray boost to biological target volume, 5 fractions per week. Study group 3: 5.9 Gray x 10, 5 fractions per week. Study group 4 (planning target volumes: 100 millilitres - 300 millilitres): 3.5 Gray x 10, 5 fractions per week. Phase II dosis: to be chosen based on results of phase I study.
Study NCT03023657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Detection of arousal
Description: Detecting facial microexpression before visible facial expressions in patient with disorder of consciousness after severe brain injury
Study NCT02804282 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: sc2Wear Furosemide
Description: Drug-device combination product of buffered furosemide injection, (Furosemide Injection Solution), 8 mg/mL, and patch pump (sc2Wear Furosemide Pump)
Study NCT00913198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV CP-4126
Description: 1250 mg/m2/d, IV (in the vein) on day 1, 8 and 15 of each 4 week cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT01926275 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NPPV+IMT
Description: noninvasive positive pressure ventilation and inspiratory muscle training
Study NCT01926275 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: NPPV+IMT
Description: noninvasive positive pressure ventilation and inspiratory muscle training
Study NCT01926275 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NPPV
Description: noninvasive positive pressure ventilation
Study NCT01832480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTZ 2 g
Description: MTZ 2 g
Study NCT03049969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS stimulation
Description: up to 4.0 mA, dorsolateral prefrontal cortex (montage dependent on specific area of deficit) while completing cognitive training tasks
Study NCT03083197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline 7 days
Description: loading dose 200mg PO, then 100mg PO every 12 hours for 7 days
Study NCT03083197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline 3 days
Description: loading dose 200mg PO, then 100mg PO every 12 hours for 3 days
Study NCT03083197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin 3 days
Description: loading dose 1000mg PO on day 1, then 500mg PO every 24 hours on days 2 and 3
Study NCT00510887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib 1.6 mg/m2 on days 1 and 8 of each 28-day cycle
Study NCT00510887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 IV on day 1
Study NCT00510887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m2 IV on days 1,2,3
Study NCT00510887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Mitoxantrone 10 mg/m2 IV on day 2
Study NCT00510887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20 mg orally on days 1,2,3,4,5
Study NCT02568683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib
Description: ENTO spray dried dispersion tablets administered orally twice daily while in a fasted state
Study NCT01926275 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: NPPV
Description: noninvasive positive pressure ventilation
Study NCT01926275 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NPPV
Description: noninvasive positive pressure ventilation
Study NCT01926275 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: IMT
Description: inspiratory muscle training
Study NCT01926275 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IMT
Description: inspiratory muscle training
Study NCT01926275 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMT
Description: inspiratory muscle training
Study NCT04482868 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Percutaneous screw fixation through K-wire-assisted reduction and maintenance
Description: Percutaneous screw fixation for acute scaphoid fractures through K-wire-assisted reduction and maintenance
Study NCT04482868 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous screw fixation through K-wire-assisted reduction and maintenance
Description: Percutaneous screw fixation for acute scaphoid fractures through K-wire-assisted reduction and maintenance
Study NCT02100319 — intervention group
Intervention type: DRUG
Intervention: Azilsartan
Description: Azilsartan tablets
Study NCT03166007 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Optimised bowel care
Description: During a 1 hour outpatient appointment, the participants' existing bowel care routine will be reviewed and optimised. For example, explaining the necessity of adequate fluid intake. No change in medication will be advocated. The participants in this group will also receive one telephone call per week during the following 6 week period to further discuss their bowel management and again at 24 week time point.
Study NCT03166007 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optimised bowel care
Description: During a 1 hour outpatient appointment, the participants' existing bowel care routine will be reviewed and optimised. For example, explaining the necessity of adequate fluid intake. No change in medication will be advocated. The participants in this group will also receive one telephone call per week during the following 6 week period to further discuss their bowel management and again at 24 week time point.
Study NCT02518074 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hearing and Vestibular Interactions
Description: in two body positions (standing / supine) and three gravity conditions (weightlessness hyper gravity and normal gravity).
Study NCT02933723 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Draw
Description: Sampling 3 blood draws Day 0 for humoral and CMI 30 ml prior to vaccination (up to 2 week prior to vaccination) Day 7 for CMI 20 ml (+/- 1 day) Day 28 for humoral 10 ml (+/- 3 days)